Ponvory is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator that has been approved for treating relapsing forms of MS. Image Credit: Tero Vesalainen / Shutterstock.

France-based Juvisé Pharmaceuticals has acquired global marketing rights, excluding the US and Canada, for Johnson & Johnson (J&J)’s multiple sclerosis (MS) therapy Ponvory (ponesimod).

The French company will also assume worldwide manufacturing duties for Ponvory from sites based in France and Switzerland. Juvisé secured the Ponvory rights from J&J’s subsidiary Actelion Pharmaceuticals.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The financial details of the deals were not disclosed, with Juvisé adding that the deal was funded by “a mix of capital increase, additional debt, and shareholder loan”. Furthermore, a European private credit manager, Bpifrance and Pemberton Asset Management, acquired a minority stake in Juvisé to fund Ponvory’s acquisition.

Ponvory is a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator. The drug was the first oral disease-modifying treatment (DMT) to demonstrate superior efficacy compared to Sanofi’s Aubagio (teriflunomide), another first-line therapy for MS.

Ponvory has been approved by multiple regulatory bodies, including the European Medicines Agency (EMA) as a first-line treatment for adults with relapsing forms of MS. In December 2023, J&J sold the North American marketing rights for Ponvory to Vanda Pharmaceuticals for $100m.

Juvisé expects Ponvory to generate significant sales this year. The company forecast its revenues to reach €180m ($194m), up by approximately 38% compared to 2023. Ponvory’s sales are expected to account for about 24% of the total profits.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The MS market is expected to generate $41.1bn in sales across 68 global markets by 2030, as per a GlobalData market analysis report. The European market for MS therapies is expected to be worth $8.8m in the same period. Roche’s Ocrevus (ocrelizumab) and Novartis’ Kesimpta (ofatumumab) are expected to be market leaders in the space, bringing in sales of $6.3bn and $4.5bn in 2030, respectively.

GlobalData is the parent company of Pharmaceutical Technology.

Juvisé has previously acquired marketing rights to multiple therapies from top pharmaceutical companies such as Novartis, AstraZeneca, and AbbVie. In 2022, the company acquired global rights for the combination antibiotic Pylera (bismuth subcitrate potassium, metronidazole, and tetracycline) from AbbVie. In 2019, Juvisé bought the global rights for two cancer therapies, Arimidex (anastrozole) and Casodex (bicalutamide), from AstraZeneca for an upfront payment of $181m.